SP1 and prostate carcinoma: Here, we evaluated whether the “biomarker signature” of FLIP, Sp1, and Sp3 can predict the development of prostate cancer recurrence by immunohistochemical evaluation of tissue samples obtained from patients who underwent prostatectomy as primary treatment for prostate cancer and were observed for at least 5 years with PSA measurements.